Tenax Therapeutics (NASDAQ:TENX – Get Free Report) and Newron Pharmaceuticals (OTCMKTS:NWPHF – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.
Profitability
This table compares Tenax Therapeutics and Newron Pharmaceuticals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Tenax Therapeutics | N/A | -65.79% | -58.31% |
Newron Pharmaceuticals | N/A | N/A | N/A |
Valuation and Earnings
This table compares Tenax Therapeutics and Newron Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Tenax Therapeutics | N/A | N/A | -$7.71 million | N/A | N/A |
Newron Pharmaceuticals | $6.82 million | 22.30 | -$17.63 million | N/A | N/A |
Risk & Volatility
Tenax Therapeutics has a beta of 2.25, suggesting that its stock price is 125% more volatile than the S&P 500. Comparatively, Newron Pharmaceuticals has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Tenax Therapeutics and Newron Pharmaceuticals, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Tenax Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Newron Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
Tenax Therapeutics presently has a consensus target price of $480.00, suggesting a potential upside of 13,693.10%. Given Tenax Therapeutics’ higher possible upside, research analysts clearly believe Tenax Therapeutics is more favorable than Newron Pharmaceuticals.
Institutional and Insider Ownership
1.7% of Tenax Therapeutics shares are owned by institutional investors. 1.9% of Tenax Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Tenax Therapeutics beats Newron Pharmaceuticals on 6 of the 9 factors compared between the two stocks.
About Tenax Therapeutics
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
About Newron Pharmaceuticals
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.